LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


Ablynx Announces Research Collaboration With Algeta to Explore the Therapeutic Potential of Nanobody-radioisotope Drug Candidates


« Back to News


Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx

Last Wednesday, Ablynx NV (Euronext Brussels: ABLX) announced that it has entered into a research collaboration with Algeta ASA (Oslo: ALGETA) to explore the combination of Nanobodies with thorium-227 using Algeta’s proprietary Targeted Thorium Conjugate, or TCC technology.   

The two companies will work together to establish if a Nanobody-Thorium 227 conjugate can be generated and whether the resulting conjugate can target a specific population of tumour cells. Ablynx will provide access to novel Nanobodies against a specific, undisclosed target. Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227.

Targeted Thorium Conjugates, or TTCs, are experimental anti-cancer agents being developed by Algeta that are made by linking the thorium-227 radioisotope to a cancer targeting molecule. Thorium-227 has potential value in the treatment of cancer as it has a localized tumoricidal effect due of the very short range of the alpha particles.

Specific features of the Ablynx Nanobodies (small size, improved stability and robustness, potential for tumour-specific formatting, ability to modulate half life) could make them ideal for delivering thorium-227 to a tumour. The physical action of alpha particles reduces the possibility of drug resistance observed with conventional chemotherapy and biologics.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design